Modulation of type I interferon responses to influence tumor-immune cross talk in PDAC

Cattolico, C., Bailey, P. and Barry, S. T. (2022) Modulation of type I interferon responses to influence tumor-immune cross talk in PDAC. Frontiers in Cell and Developmental Biology, 10, 816517. (doi: 10.3389/fcell.2022.816517) (PMID:35273962) (PMCID:PMC8902310)

[img] Text
266690.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Immunotherapy has revolutionized the treatment of many cancer types. However, pancreatic ductal adenocarcinomas (PDACs) exhibit poor responses to immune checkpoint inhibitors with immunotherapy-based trials not generating convincing clinical activity. PDAC tumors often have low infiltration of tumor CD8+ T cells and a highly immunosuppressive microenvironment. These features classify PDAC as immunologically “cold.” However, the presence of tumor T cells is a favorable prognostic feature in PDAC. Intrinsic tumor cell properties govern interactions with the immune system. Alterations in tumor DNA such as genomic instability, high tumor mutation burden, and/or defects in DNA damage repair are associated with responses to both immunotherapy and chemotherapy. Cytotoxic or metabolic stress produced by radiation and/or chemotherapy can act as potent immune triggers and prime immune responses. Damage- or stress-mediated activation of nucleic acid-sensing pathways triggers type I interferon (IFN-I) responses that activate innate immune cells and natural killer cells, promote maturation of dendritic cells, and stimulate adaptive immunity. While PDAC exhibits intrinsic features that have the potential to engage immune cells, particularly following chemotherapy, these immune-sensing mechanisms are ineffective. Understanding where defects in innate immune triggers render the PDAC tumor–immune interface less effective, or how T-cell function is suppressed will help develop more effective treatments and harness the immune system for durable outcomes. This review will focus on the pivotal role played by IFN-I in promoting tumor cell–immune cell cross talk in PDAC. We will discuss how PDAC tumor cells bypass IFN-I signaling pathways and explore how these pathways can be co-opted or re-engaged to enhance the therapeutic outcome.

Item Type:Articles
Additional Information:This review was supported with financial grants by PRECODE (EU grant number: 861196).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Bailey, Dr Peter
Authors: Cattolico, C., Bailey, P., and Barry, S. T.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Frontiers in Cell and Developmental Biology
Publisher:Frontiers Media
ISSN:2296-634X
ISSN (Online):2296-634X
Copyright Holders:Copyright © 2022 Cattolico, Bailey and Barry
First Published:First published in Frontiers in Cell and Developmental Biology 10: 816517
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
306698PancREatic Cancer OrganoiDs rEsearch NetworkPeter BaileyEuropean Commission (EC)861196CS -Translational Research Centre